ATE448797T1 - Zusammensetzung enthaltend il-1ra als interleukin-1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe - Google Patents

Zusammensetzung enthaltend il-1ra als interleukin-1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe

Info

Publication number
ATE448797T1
ATE448797T1 AT97906551T AT97906551T ATE448797T1 AT E448797 T1 ATE448797 T1 AT E448797T1 AT 97906551 T AT97906551 T AT 97906551T AT 97906551 T AT97906551 T AT 97906551T AT E448797 T1 ATE448797 T1 AT E448797T1
Authority
AT
Austria
Prior art keywords
release polymer
hyaluronan
interleukin
delayed
inhibitor
Prior art date
Application number
AT97906551T
Other languages
English (en)
Inventor
David Collins
Michael Bevilacqua
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/798,414 external-priority patent/US6096728A/en
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE448797T1 publication Critical patent/ATE448797T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
AT97906551T 1996-02-09 1997-02-10 Zusammensetzung enthaltend il-1ra als interleukin-1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe ATE448797T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1141996P 1996-02-09 1996-02-09
US3278996P 1996-12-06 1996-12-06
US3624197P 1997-01-23 1997-01-23
US08/798,414 US6096728A (en) 1996-02-09 1997-02-07 Composition and method for treating inflammatory diseases
PCT/US1997/002131 WO1997028828A1 (en) 1996-02-09 1997-02-10 Composition comprising interleukin-1 inhibitor and controlled release polymer

Publications (1)

Publication Number Publication Date
ATE448797T1 true ATE448797T1 (de) 2009-12-15

Family

ID=27486083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97906551T ATE448797T1 (de) 1996-02-09 1997-02-10 Zusammensetzung enthaltend il-1ra als interleukin-1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe

Country Status (19)

Country Link
EP (1) EP0904112B1 (de)
JP (2) JP4344404B2 (de)
KR (1) KR20040010739A (de)
CN (1) CN1215340A (de)
AT (1) ATE448797T1 (de)
AU (1) AU724960C (de)
BR (1) BR9707325A (de)
CA (2) CA2244664C (de)
CZ (1) CZ299025B6 (de)
DE (1) DE69739656D1 (de)
EA (2) EA001792B1 (de)
ES (1) ES2334726T3 (de)
HU (1) HU230160B1 (de)
IL (1) IL125552A0 (de)
MX (1) MX9806191A (de)
NO (1) NO983543L (de)
NZ (2) NZ331163A (de)
SK (1) SK288144B6 (de)
WO (1) WO1997028828A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
HK1042114B (zh) 1998-10-23 2006-09-29 Amgen K-A, Inc. 与mp1受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
AT406054B (de) * 1998-11-04 2000-02-25 Andreas Bernkop-Schnuerch Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
EP1203583B1 (de) * 1999-06-21 2005-12-07 Santen Pharmaceutical Co., Ltd. Arzneimittel für die rheumatoide arthritis
EP1200127B1 (de) * 1999-07-21 2008-06-25 Omeros Corporation Spüllösungen und verfahren zur schmerzhemmung, entzündungshemmung und hemmung des knorpelabbaus
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU5943201A (en) * 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
US7324635B2 (en) 2000-05-04 2008-01-29 Telemaze Llc Branch calling and caller ID based call routing telephone features
EP2241328A1 (de) * 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 Inhibitoren zur Behandlung von Erkrankungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
MXPA04006875A (es) * 2002-01-18 2004-12-06 Control Delivery Sys Inc Sistema de gel polimerico para suministro controlado de cofarmacos.
CA2485166A1 (en) 2002-05-21 2003-12-04 Amgen Inc. Substituted pyrimidinone and pyridinone compounds
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
JP2007531738A (ja) 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド ＩＬ−１ｒａの凝集を低下させる方法
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
EP2664334B1 (de) * 2004-12-30 2015-03-04 Genzyme Corporation Therapien zur intraartikulären Viskosupplementation
EP1896072A4 (de) * 2005-06-24 2013-01-09 Univ Duke System zur direkten heilmittelverabreichung auf der basis wärmegesteuerter biopolymere
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
EP2217258B1 (de) 2007-11-14 2014-03-26 General Regeneratives Limited Verwendung eines interleukin-1-rezeptor-antagonisten als myeloprotektives mittel
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
EP2620139B1 (de) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1-Rezeptorantagonisten-reiche Lösungen
KR200451958Y1 (ko) * 2008-10-09 2011-01-21 (주)에이치시티 모바일기기용 카드형 안테나장치
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
DE202009017772U1 (de) 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
KR20150080033A (ko) * 2011-02-08 2015-07-08 애브비 인코포레이티드 골관절염 및 통증의 치료 방법
DK2672985T3 (en) 2011-02-11 2016-06-27 Swedish Orphan Biovitrum Ab (Publ) CITRATFRIE pharmaceutical formulations comprising anakinra
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
AU2012300815A1 (en) 2011-09-02 2014-02-20 Novozymes Biopharma Dk A/S Oral formulations containing hyaluronic acid for sustained drug release
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
EP3054982B1 (de) * 2013-10-08 2019-05-01 Ascendis Pharma A/S Hydrogel-konjugiertes il-1ra prodrug
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
CZ309295B6 (cs) * 2015-03-09 2022-08-10 Contipro A.S. Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
IL269506B2 (en) 2017-03-22 2024-04-01 Genentech Inc Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
JP7241782B2 (ja) * 2018-06-22 2023-03-17 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 顎関節変性疾患の治療用の持続放出性組成物およびその方法
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US12370240B2 (en) 2018-11-28 2025-07-29 Genascence Corporation Methods and compositions for treating osteoarthritis
CN114206366A (zh) 2019-08-08 2022-03-18 艾维登斯医疗公司 基于微球的可注射塞来昔布制剂
EP4526469A1 (de) 2022-05-16 2025-03-26 Institut National de la Santé et de la Recherche Médicale Verfahren zur beurteilung der erschöpfung von hämatopoetischen stammzellen durch chronische entzündung

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
CA2485553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation Tumor necrosis factor - .alpha. and - .beta. receptors
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
AU7683391A (en) 1990-04-27 1991-11-27 Upjohn Company, The Modified interleukin-1 inhibitors
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
NO940913L (no) * 1993-03-26 1994-09-27 Bristol Myers Squibb Co Preparater for kontrollert frigivelse av biologisk aktiv TGF-
JPH06321803A (ja) * 1993-05-17 1994-11-22 Kirin Brewery Co Ltd 水溶性ペプチドホルモンの徐放性製剤
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
AU8016094A (en) * 1993-10-12 1995-05-04 Mary Lake Polan Method of contraception
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
JPH10503179A (ja) 1994-06-24 1998-03-24 イミュネックス・コーポレーション 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法
IT1269989B (it) 1994-09-21 1997-04-16 Dompe Spa Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria

Also Published As

Publication number Publication date
AU724960B2 (en) 2000-10-05
EA001792B1 (ru) 2001-08-27
NO983543L (no) 1998-10-08
NZ503548A (en) 2001-09-28
AU724960C (en) 2002-08-15
HU230160B1 (hu) 2015-09-28
AU2121397A (en) 1997-08-28
CA2539273A1 (en) 1997-08-14
EA199800694A1 (ru) 1999-02-25
BR9707325A (pt) 1999-04-13
SK288144B6 (sk) 2013-12-02
MX9806191A (es) 1998-10-31
EP0904112A1 (de) 1999-03-31
WO1997028828A1 (en) 1997-08-14
DE69739656D1 (de) 2009-12-31
JP2001500472A (ja) 2001-01-16
NO983543D0 (no) 1998-07-31
CA2539273C (en) 2014-02-04
SK103698A3 (en) 2001-01-18
HUP9902612A3 (en) 2001-11-28
KR20040010739A (ko) 2004-01-31
CN1215340A (zh) 1999-04-28
ES2334726T3 (es) 2010-03-15
CZ237398A3 (cs) 1999-09-15
CA2244664A1 (en) 1997-08-14
IL125552A0 (en) 1999-03-12
EP0904112B1 (de) 2009-11-18
HUP9902612A2 (hu) 1999-11-29
CZ299025B6 (cs) 2008-04-02
EA200000825A1 (ru) 2001-02-26
JP4344404B2 (ja) 2009-10-14
NZ331163A (en) 2000-07-28
JP2007211027A (ja) 2007-08-23
CA2244664C (en) 2008-06-03

Similar Documents

Publication Publication Date Title
DE69739656D1 (de) 1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
FI973292A7 (fi) Substituoituja isoksatsoleja tulehduksen hoitamiseksi
BR9710372A (pt) Composto composi-Æo farmac-utica e processos para o tratamento de uma doen-a inflamatÄria e de doen-as mediadas pela cliclooxigenase
DK0995747T3 (da) Substituterede sulfonylphenylheterocykler som cyclooxygenase-2- og 5-lipoxygenase-inhibitorer
EP1090637A3 (de) Zubereitungen und Verfahren zur Behandlung oder Prävention von entzündlichen Erkrankungen
ATE88346T1 (de) Zusammensetzung mit gehalt an einem nichtsteroiden entzuendungshemmenden mittel und einem nichtbakterizidwirksamen tetracyclin.
NO981392L (no) Substituerte pyrazolylbenzensulfonamider for anvendelse i veterinµrterapi som antiinflammatorisk middel
FI962249A7 (fi) Substituoituja pyratsolyylibentseenisulfonamideja tulehduksen hoitoa varten
BR9908182A (pt) Composições de proteìna de matriz para cura deferidas
ZA919317B (en) Novel hydroxamic acid and N-hydroxyurea derivatives and their use.
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
SE9604751D0 (sv) New therapy
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
DK0912185T3 (da) Nye farmaceutiske sammensætninger indeholdende steroidnitratesterderivater, der kan anvendes som antiinflammatoriske lægemidler
PT782441E (pt) Controlo farmaceutico da inflamacao
BR0308957A (pt) Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação
CA2227711A1 (en) Thioctic acid metabolites and methods of use thereof
PT900563E (pt) Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas
BR9610211A (pt) Composições farmacêuticas baseadas em gel tipo gliceril poli(meta)acrilato
DK0951294T3 (da) Sårhelende formuleringer indeholdende humanplasmafibronectin
NO20031650D0 (no) Nye legemidler for leversykdommer
ATE189395T1 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
PT841933E (pt) Composicoes do inibidor bowman-birk para tratamento de doencas inflamatorias
FI950649L (fi) Substituoidut sykloheksanoliesterit, niiden käyttö sairauksien hoitamiseksi ja farmaseuttiset valmisteet

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties